WO2002018584A3 - Xage-1, a gene expressed in multiple cancers, and uses thereof - Google Patents
Xage-1, a gene expressed in multiple cancers, and uses thereof Download PDFInfo
- Publication number
- WO2002018584A3 WO2002018584A3 PCT/US2001/027258 US0127258W WO0218584A3 WO 2002018584 A3 WO2002018584 A3 WO 2002018584A3 US 0127258 W US0127258 W US 0127258W WO 0218584 A3 WO0218584 A3 WO 0218584A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- proteins
- xage
- cancer
- provides
- analogs
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 abstract 4
- 102100039490 X antigen family member 1 Human genes 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 229940127121 immunoconjugate Drugs 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the surprising discovery that XAGE-1 is translated as two proteins, a 9 kD protein, termed p9, and a 16.3 kD protein, termed p16. The invention further relates to the surprising discovery that XAGE-1 is expressed in a number of important human cancers, specifically: prostate cancer, lung cancer, ovarian cancer, breast cancer, glioblastoma, pancreatic cancer, T cell lymphoma, melanoma, and histocytic lymphoma. The proteins p9 and p16, immunogenic fragments thereof, analogs of these proteins, and nucleic acids encoding these proteins, fragments, or analogs, can be administered to persons with XAGE-1 expressing cancers to raise or augment an immune response to the cancer. The invention further provides nucleic acid sequences encoding the proteins, as well as expression vectors, host cells, and antibodies to the proteins. Further, the invention provides immunoconjugates that comprise an antibody to p16 or to p9, and an effector molecule, such as a label, a radioisotope, or a toxin. The invention also provides methods of inhibiting the growth of XAGE-1 expressing cells by contacting them with immunoconjugates comprising an anti- p9 or p16 antibody and a toxic moiety. Further, the invention provides kits for detecting the presence of p9 or p16 in a sample.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001287004A AU2001287004A1 (en) | 2000-09-01 | 2001-08-31 | Xage-1, a gene expressed in multiple cancers, and uses thereof |
| US10/363,233 US20040087772A1 (en) | 2001-08-31 | 2001-08-31 | Xage-1, a gene expressed in multiple cancers, and uses thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22968400P | 2000-09-01 | 2000-09-01 | |
| US60/229,684 | 2000-09-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002018584A2 WO2002018584A2 (en) | 2002-03-07 |
| WO2002018584A3 true WO2002018584A3 (en) | 2003-01-16 |
Family
ID=22862271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/027258 WO2002018584A2 (en) | 2000-09-01 | 2001-08-31 | Xage-1, a gene expressed in multiple cancers, and uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2001287004A1 (en) |
| WO (1) | WO2002018584A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572887B2 (en) | 2003-04-08 | 2009-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Gene expressed in prostate cancer, methods and use thereof |
| US20130171178A1 (en) * | 2003-12-12 | 2013-07-04 | The Government Of The United States As Represented By The Secretary Of Health And Human Services | Immunogenic Peptides of Xage-1 |
| CN103293308B (en) * | 2013-05-24 | 2014-11-26 | 尉军 | Amino acid sequence for detecting tumor marker P16 antigenic epitope and application of amino acid sequence |
| US20210115099A1 (en) | 2016-11-07 | 2021-04-22 | Immunocore Limited | Peptides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000828A2 (en) * | 1999-06-30 | 2001-01-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| WO2001042451A2 (en) * | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
| EP1179589A1 (en) * | 2000-08-08 | 2002-02-13 | F. Hoffmann-La Roche Ag | MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential |
-
2001
- 2001-08-31 WO PCT/US2001/027258 patent/WO2002018584A2/en active Application Filing
- 2001-08-31 AU AU2001287004A patent/AU2001287004A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000828A2 (en) * | 1999-06-30 | 2001-01-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| WO2001042451A2 (en) * | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
| EP1179589A1 (en) * | 2000-08-08 | 2002-02-13 | F. Hoffmann-La Roche Ag | MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential |
Non-Patent Citations (4)
| Title |
|---|
| BRINKMANN U ET AL: "Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 7, 1 April 1999 (1999-04-01), pages 1445 - 1448, XP002177257, ISSN: 0008-5472 * |
| DATABASE EMBL [online] 23 August 2000 (2000-08-23), LIU X ET AL: "Homo sapiens XAGE-1 mRNA, complete cds.", XP002210234, retrieved from EBI Database accession no. AF251237 * |
| LIU XIU FEN ET AL: "XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma.", CANCER RESEARCH, vol. 60, no. 17, 1 September 2000 (2000-09-01), pages 4752 - 4755, XP002210232, ISSN: 0008-5472 * |
| ZENDMAN ALBERT J W ET AL: "Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis.", INTERNATIONAL JOURNAL OF CANCER, vol. 97, no. 2, January 2002 (2002-01-01), pages 195 - 204, XP002210233, ISSN: 0020-7136 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001287004A1 (en) | 2002-03-13 |
| WO2002018584A2 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seymour et al. | A processed multidomain Mycoplasma hyopneumoniae adhesin binds fibronectin, plasminogen, and swine respiratory cilia | |
| Saito et al. | Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential | |
| WO2000073801A3 (en) | Breast, gastric and prostate cancer associated antigens and uses therefor | |
| NO20021992L (en) | Anti-prostate stem cell antigen (PSCA) antibody preparation and methods of use | |
| WO2004024750A3 (en) | Cd44-binding ligands | |
| NZ331866A (en) | Compounds for immunotherapy and immunodiagnosis of prostate cancer | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| BRPI0516264A (en) | nucleic acid molecule, nucleotide sequence, expression cassette, expression vector, cell, methods for expressing a recombinant antibody or fragment thereof, to enhance expression of a recombinant antibody or fragment thereof, to produce a recombinant antibody or fragment thereof and an antibody preparation and for detecting an irt product in a sample, antibody and pharmaceutical composition | |
| WO2004101756A3 (en) | Ovr110 antibody compositions and methods of use | |
| WO2000020587A3 (en) | Cancer associated antigens and uses therefor | |
| CN105277712B (en) | A kind of method for identifying the modification of lysine ε amino side chains monomethylation | |
| WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
| AU3217100A (en) | Methods of use of a novel lysyl oxidase-related protein | |
| WO2003033520A3 (en) | Anticancer vaccine and diganostic methods and reagents | |
| AU2003287115A1 (en) | Fluorescent proteins from copepoda species and methods for using same | |
| WO2004067564B1 (en) | Compositions against cancer antigen liv-1 and uses thereof | |
| WO2002018584A3 (en) | Xage-1, a gene expressed in multiple cancers, and uses thereof | |
| Jurnecka et al. | Bordetella pertussis and Bordetella bronchiseptica filamentous hemagglutinins are processed at different sites | |
| WO2001064913A3 (en) | Cell cycle proteins associated with rad9, compositions and methods of use | |
| Andoh et al. | Disulfide bridges in proteins linking DNA in cultured mouse fibroblasts, strain L· P3 | |
| Host et al. | Enzymatic methylation of the Mycobacterium tuberculosis heparin-binding haemagglutinin | |
| WO2005058944A3 (en) | Immunogenic peptides fragments of xage-1 | |
| WO2003066808A3 (en) | Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells | |
| WO1999029724A3 (en) | Dna encoding pasteurella multocida outer membrane protein | |
| WO2001000874A3 (en) | Cancer associated antigens and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 10363233 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |